On 27.06.2019, CBmed GmbH and Aimed Bio Inc. joined hands in the field of precision oncology. Do-Hyun Nam (CEO and founder of Aimed Bio) and Robert Lobnig signed a Memorandum of Understanding that sets the stage for a long-term collaboration starting end of 2019 based on a COMET funded project in the cancer area. The research work of Dr. Nam, developed originally at Samsung Medical Center in Seoul in the Republic of Korea led to the spin-off of Aimed Bio. Together with research activities in Singapore on Hepatocellular Carcinoma, this covers an outstanding history related to personalized drug screening in precision oncology. Together with CBmed, both partners aim for combining their individual expertise into next generation precision oncology services with dedicated drug screening of cancer patients.